1. Home
  2. SBI vs YARW Comparison

SBI vs YARW Comparison

Compare SBI & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

HOLD

Current Price

$7.67

Market Cap

108.9M

Sector

Finance

ML Signal

HOLD

Logo Yarrow Bioscience Inc. Common Stock

YARW

Yarrow Bioscience Inc. Common Stock

N/A

Current Price

$41.43

Market Cap

111.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SBI
YARW
Founded
1992
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.9M
111.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SBI
YARW
Price
$7.67
$41.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.8K
20.8K
Earning Date
01-01-0001
N/A
Dividend Yield
4.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.51
$31.55
52 Week High
$8.01
$42.50

Technical Indicators

Market Signals
Indicator
SBI
YARW
Relative Strength Index (RSI) 35.66 N/A
Support Level $7.58 N/A
Resistance Level $7.90 N/A
Average True Range (ATR) 0.08 0.00
MACD -0.01 0.00
Stochastic Oscillator 29.41 0.00

Price Performance

Historical Comparison
SBI
YARW

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.

About YARW Yarrow Bioscience Inc. Common Stock

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.

Share on Social Networks: